alcohol use disorder

Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotech firm based in Vancouver, has been granted a new patent by the United States Patent and Trademark Office. As the company stated in a press release, this approval marks a significant milestone in Clearmind's efforts to develop...

Whether it's labeled as alcoholism or binge drinking, unhealthy alcohol use poses a health and safety risk. Alarming 2022 data from the National Institute on Alcohol Abuse and Alcoholism show that nearly 30 million people ages 12 and older (10.5% in this age group) had alcohol use disorder (AUD) in...

Welcome to a new episode of our Benzinga Psychedelics Podcast. We are joined herein by executives of Clearmind Medicine (NASDAQ:CMND), a biotech company developing a proprietary, psychoactive yet non-hallucinogenic treatment for a diverse array of addictive behaviors, with Alcohol Use Disorder (aka...

Awakn Life Sciences Corp. (OTC: AWKNF), a biotech firm focused on developing therapies for addiction, with a primary emphasis on Alcohol Use Disorder (AUD), has taken a big step toward Phase III clinical trial initiation today. The company has submitted a Clinical Trial Application...

Starting this October, scientists at Imperial College London’s (ICL) Centre for Psychedelic Research will assess psilocybin-assisted therapy for gambling addiction, noted Psychedelic Spotlight.  Government-funded, the study will focus on understanding brain function in the gambling...

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) sold its London subsidiary and healthcare clinic. The deal comes on the heels of a recently announced business strategy change. What Happened: The clinic’s new proprietor, a joint venture named Awakn Via Amitis Ltd., is co-owned by...

President Joe Biden’s youngest brother, Frank Biden, recently called SiriusXM radio host Michael Smerconish and revealed that the U.S. President has been “very open-minded” in conversations held between the two around the medical benefits of psychedelics. “The question is...

Biopharma company FSD Pharma (NASDAQ: HUGE) has inked a Letter of Intent (LOI) with private business 1319741 B.C. Ltd., to be renamed Celly Nutrition Inc. (Celly Nu,) to set up the terms and conditions following which the latter will be granted exclusive rights to recreational applications for...

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) is set to exit ketamine healthcare services to focus solely on research and development of therapeutics to treat addiction and licensing of its intellectual property (IP.) "Streamlining our operations and increasing our focus on the...

The peer-reviewed journal Psychology of Addictive Behaviors published by the American Psychological Association (APA) released a new analysis by Fluence, NYU and UC-SF of a clinical trial of psilocybin-assisted psychotherapy for the treatment of Alcohol Use Disorder (AUD.)  What triggered...

Clearmind Medicine Inc. (NASDAQ: CMND), an Israel-based biotech company advancing the clinical stage for an MEAI-based compound targeting Alcohol Use Disorder (AUD,) has selected Yale School of Medicine’s Psychiatry Dept. as the first U.S. site for its Phase 1/2a trial on proprietary CMND-100...

Clearmind Medicine Inc. (NASDAQ: CMND), an Israeli biotech company received approval from the IMCA center’s Ethics Committee for the announced Phase 1/2 clinical trial assessing its proprietary MEAI-based compound, CMND-100, for the treatment of Alcohol Use Disorder (AUD.) Clearmind ...

Alcohol Use Disorder (AUD) is one of the top-targeted health issues by biopharma companies. In the case of Clearmind Medicine (NASDAQ: CMND), the Israel-based company is going at it through its MEAI-based proprietary drug candidate, CMND-100. After the novel compound’s positive...

The UK-based psychedelics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) reported on its financial results and business highlights for the three and twelve months ended Jan. 31, 2023.   The company, which developed a specialty ketamine treatment for alcohol addiction,...

Clinical-stage private biotech company Beckley Psytech Ltd has initiated a Phase 2a clinical study on its synthetic formulation of 5-MeO-DMT for the treatment of Alcohol Use Disorder (AUD) and will soon begin patient enrollment.  CEO ‍Cosmo Feilding Mellen said the company’...